Braveheart Bio (NASDAQ:BRVE) Raised to “Hold” at Wall Street Zen

Braveheart Bio (NASDAQ:BRVE) was upgraded by stock analysts at Wall Street Zen to a “hold” rating in a research note issued to investors on Saturday.

Braveheart Bio Stock Performance

Shares of BRVE stock opened at $27.03 on Friday. Braveheart Bio has a 1-year low of $24.61 and a 1-year high of $32.00.

Insider Activity at Braveheart Bio

In other Braveheart Bio news, Director Orbimed Advisors Llc bought 1,940,000 shares of the stock in a transaction dated Friday, August 7th. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $34,920,000.00. Following the completion of the acquisition, the director owned 11,901,826 shares of the company’s stock, valued at approximately $214,232,868. This trade represents a 19.47% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Erez Chimovits acquired 1,940,000 shares of Braveheart Bio stock in a transaction that occurred on Friday, August 7th. The shares were bought at an average cost of $18.00 per share, with a total value of $34,920,000.00. Following the transaction, the director owned 11,901,826 shares in the company, valued at $214,232,868. This represents a 19.47% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders purchased a total of 8,751,942 shares of company stock valued at $157,534,956 over the last ninety days.

Braveheart Bio Company Profile

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.